R2T Biopharma

R2T Biopharma Inc.(“R2T”) is an innovative nutraceutical company. R2T provides varieties of customized solutions ranging from therapeutic nutritional supplements using liposomal technology to therapeutic cancer vaccines. R2T is dedicated to provide therapeutic solutions that will enhance the patient’s lifestyle, dietary habits, and nutritional balance for all age. When the ‘Right to Try’ bill was signed and passed in the United States on May 30, 2018, R2T mission has been further strengthen to bring hope and chance to patients with degenerative diseases and cancers. R2T (Right to Try) Biopharma name reminds our mission every day.

R2T focused on developing a technology that can deliver nutrients into human body more effectively. The nutrient in the traditional oral dosage is metabolized and broken down even before going into circulation. After extensive research and clinical experience, R2T developed a unique liposomal technology (Drug Delivery System). The necessary nutrients are delivered into the body and increase the absorption rate using the liposomal technology. R2T liposomal supplement has been recognized by patients with degenerative diseases and cancers.

While R2T liposomal supplement helps to protect and rehabilitate from degenerative diseases and cancers, R2T researched to find ways to treat cancer with low toxicity with high efficacy.  Cancer is one of the leading causes of death worldwide; however, traditional cancer therapies (surgery, radiation, and chemotherapy) represent a trade-off between levels of low specificity, high toxicity and partial efficacy. Furthermore, it cannot eliminate residual cancer diseases, resulting in tumor relapse. 

R2T acquired a company named Xeme Biopharma Inc., a bio tech company that has been dedicated to the development of innovative Therapeutic Cancer Vaccines named Aggregon. With a focus on oncology, immunology and infectious diseases, the Aggregon vaccine is customized, rapidly produced, easy to administer, non-toxic and safe for hematologic cancer and solid tumor. R2T continues to research ways to provide solution for incurable and degenerative diseases.